drugset / Trial / NCT06750133
Universal CNK-UT Therapy for Refractory aGVHD
Phase 1
Recruiting
23 enrolled
First Affiliated Hospital of Zhejiang University
ST Phi Therapeutics Co., Ltd · collab
NaSequentialOpen-labelTreatment
Summary
This is a single arm, open-label, multi-center, pilot studies (Investigator Initiated Trial, IIT) to evaluate the safety, tolerability, efficacy, pharmacokinetics and pharmacodynamics of universal T-cells engineered with chimeric natural killer receptor (CNK-UT) to treat the patients with steroid-refractory/resistant or steroid-dependent aGVHD.
Timeline
- Start
- 2024-12-14
- Primary completion
- 2025-12-14
- Completion
- 2026-06-30
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | CNK-UT | Cell therapy | 3e+07 cells/kg | Intravenous |
| Subject | CNK-UT | Cell therapy | 6e+07 cells/kg | Intravenous |
| Subject | CNK-UT | Cell therapy | 1e+08 cells/kg | Intravenous |